All In Biotech

Drug Trial Radar · NCT01366209

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)

Last checked: Nov 20, 2026Latest source record: Apr 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 555 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

555

Actual

Start

Jun 2011

Primary completion

Feb 2014

Study completion Feb 2014

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 3, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo in patients with IPF.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • PirfenidoneDrug

    Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.

  • PlaceboDrug

    Placebo equivalent given as 3 divided doses 3 times per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52Time frame: 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • InterMune Inc.

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.